Lnc-ing epicardium-derived cells to cardiac remodelling: lncRNA-TARID as a novel antifibrotic option

Eur Heart J. 2023 May 14;44(19):1761-1763. doi: 10.1093/eurheartj/ehad058.

Authors

Xuekun Wu^{1

2}, Francesca Vacante^{1

2}, Joseph C Wu^{1

2

3}

Affiliations

¹ Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
² Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA, USA.
³ Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.

Abstract

Graphical Abstract

Intrapericardial lncRNA-TARID therapy mitigates myocardial fibrosis. The figure was designed by using BioRender.com.

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Basic Helix-Loop-Helix Transcription Factors
Demethylation
Humans
Pericardium
RNA, Antisense*
RNA, Long Noncoding* / genetics
RNA, Long Noncoding* / metabolism
Ventricular Remodeling

Substances

RNA, Antisense
RNA, Long Noncoding
TCF21 protein, human
Basic Helix-Loop-Helix Transcription Factors

Grants and funding